Compare · CARL vs WST
CARL vs WST
Side-by-side comparison of Carlsmed Inc. (CARL) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CARL and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 79.0x CARL ($293.6M).
- Over the past year, CARL is down 25.3% and WST is up 27.6% - WST leads by 52.9 points.
- WST has been more active in the news (6 items in the past 4 weeks vs 1 for CARL).
- WST has more recent analyst coverage (18 ratings vs 6 for CARL).
- Company
- Carlsmed Inc.
- West Pharmaceutical Services Inc.
- Price
- $10.86-1.00%
- $328.35-7.74%
- Market cap
- $293.6M
- $23.19B
- 1M return
- -2.07%
- -3.45%
- 1Y return
- -25.29%
- +27.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 6
- Recent ratings
- 6
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest CARL
- Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026
- Needham initiated coverage on Carlsmed with a new price target
- Director Oboyle Kevin C was granted 13,698 shares, increasing direct ownership by 79% to 31,031 units (SEC Form 4)
- Director Sidow Kevin was granted 13,698 shares, increasing direct ownership by 23% to 73,264 units (SEC Form 4)
- Director Young Philip M was granted 13,698 shares, increasing direct ownership by 79% to 31,031 units (SEC Form 4)
- Director Root Jonathan D was granted 13,698 shares, increasing direct ownership by 3% to 497,697 units (SEC Form 4)
- Carlsmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Carlsmed Inc.
- Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Carlsmed® Reports First Quarter 2026 Financial Results
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target